
|Videos|October 25, 2017
Sequencing Agents in CLL
Author(s)William G. Wierda, MD, PhD
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing agents in chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5










































